Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 2

Current and emerging therapies for the treatment of age-related macular degeneration

Authors M Vaughn Emerson, Andreas K Lauer

Published 6 June 2008 Volume 2008:2(2) Pages 377—388


M Vaughn Emerson, Andreas K Lauer

Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA

Abstract: Age-related macular degeneration (AMD) is the leading cause of vision loss in the industrialized world. In the last few decades, the mainstay of treatment for choroidal neovascularization (CNV) due to AMD has been thermal laser photocoagulation. In the last decade, photodynamic therapy with verteporfin extended treatment for more patients. While both of these treatments have prevented further vision loss in a subset of patients, improvement in visual acuity is rare. Anti-vascular endothelial growth factor A (VEGF) therapy has revolutionized the treatment of AMD-related CNV. Pegaptanib, an anti-VEGF aptamer prevents vision loss in CNV, although the performance is similar to that of photodynamic therapy. Ranibizumab, an antibody fragment and bevacizumab, a full-length humanized monoclonal antibody against VEGF have both shown promising results with improvements in visual acuity with either agent. VEGF trap, a modified soluble VEGF receptor analogue, binds VEGF more tightly than all other anti-VEGF agents and has also shown promising results in early trials. Other treatment strategies to decrease the effect of VEGF have used small interfering ribonucleic acid (RNA) to inhibit VEGF production and VEGF receptor production. Steroids, including anecortave acetate in the treatment and prevention of CNV, have shown promise in controlled trials. Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have been effective in the treatment of CNV in early studies. Squalamine lactate inhibits plasma membrane ion channels with downstream effects on VEGF, and has shown promising results with systemic administration. Other growth factors, including pigment epithelium-derived growth factor that has been administered via an adenoviral vector has shown promising initial results. In some patients ciliary neurotrophic factor is currently being studied for the inhibition of progression of geographic atrophy. Combination therapy has been investigated, and may prove to be more effective in the management of AMD-associated CNV. Ongoing and future studies will be crucial for optimizing the treatment of patients with AMD.

Keywords: age related macular degeneration, macular degeneration, VEGF, VEGF antagonist, anti-VEGF, choroidal neovascularization

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other articles by this author:

Basic training module for vitreoretinal surgery and the Casey Eye Institute Vitrectomy Indices Tool for Skills Assessment

Yeh S, Chan-Kai BT, Lauer AK

Clinical Ophthalmology 2011, 5:1249-1256

Published Date: 1 September 2011

Electroretinographic findings in transplant chorioretinopathy

Brian T Chan-Kai, Steven Yeh, Richard G Weleber, et al

Clinical Ophthalmology 2010, 4:777-783

Published Date: 14 July 2010

Readers of this article also read:

Copeptin: a new predictor for severe obstructive sleep apnea

Çınarka H, Kayhan S, Karataş M, Yavuz A, Gümüş A, Özyurt S, Cüre MC, Şahin Ü

Therapeutics and Clinical Risk Management 2015, 11:589-594

Published Date: 10 April 2015

Preparation and characterization of gadolinium-loaded PLGA particles surface modified with RGDS for the detection of thrombus

Zhang Y, Zhou J, Guo D, Ao M, Zheng Y, Wang Z

International Journal of Nanomedicine 2013, 8:3745-3756

Published Date: 1 October 2013

Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent

Accardo A, Salsano G, Morisco A, Aurilio M, Parisi A, Maione F, Cicala C, Tesauro D, Aloj L, De Rosa G, Morelli G

International Journal of Nanomedicine 2012, 7:2007-2017

Published Date: 17 April 2012

Vitreous levels of vascular endothelial growth factor in eyes with anterior hyaloidal fibrovascular proliferation

Takaki Kobayashi, Shigeki Machida, Takamitsu Fujiwara, et al

Clinical Ophthalmology 2010, 4:1043-1046

Published Date: 17 September 2010

New developments in the treatment of optic neuritis

Thomas M Jenkins, Ahmed T Toosy

Eye and Brain 2010, 2:83-94

Published Date: 18 June 2010

Review of topiramate for the treatment of epilepsy in elderly patients

BR Sommer, HH Fenn

Clinical Interventions in Aging 2010, 5:89-99

Published Date: 7 April 2010

Conjunctival-corneal melt in association with carotid artery stenosis

Rosalind MK Stewart, Say Aun Quah, Dan Q Nguyen, Stephen B Kaye

Clinical Ophthalmology 2008, 2:649-652

Published Date: 12 September 2008

Bilateral permanent concentric visual field defect secondary to severe pre-eclampsia

Mehmet Citirik, Tulay Simsek, Orhan Zilelioglu

Clinical Ophthalmology 2008, 2:465-468

Published Date: 6 June 2008

Candida endophthalmitis: A critical diagnosis in the critically ill

L Au, K Guduru, G Lipscomb, SP Kelly

Clinical Ophthalmology 2007, 1:551-554

Published Date: 15 February 2008

Agomelatine and its therapeutic potential in the depressed patient

Sidney H Kennedy, Beata S Eisfeld

Neuropsychiatric Disease and Treatment 2007, 3:423-428

Published Date: 15 September 2007